[Using recombinant activated blood coagulation factor VII for treatment of hemorrhagic syndrome in patients with thrombocytopenia].

Abstract	The review deals with an analysis of the use of recombinant activated factor clotting VII (rFVIIa) for the treatment of hemorrhagic syndrome in patients with thrombocytopenia. The review discusses cases of rFVIIa use during bleeding of different localization and different invasive interventions, a frequency of thrombotic complications and causes of the rFVlIIa insufficiency.
Authors	G M Galstian, I V Kolosova
Journal	Anesteziologiia i reanimatologiia (Anesteziol Reanimatol) 2014 Nov-Dec Vol. 59 Issue 6 Pg. 60-6 ISSN: 0201-7563 [Print] Russia (Federation)
PMID	25831706 (Publication Type: Journal Article, Review)
Chemical References	Recombinant Proteins recombinant FVIIa Factor VIIa
Topics	Factor VIIa (administration & dosage, adverse effects, therapeutic use) Hemorrhage (drug therapy, etiology) Humans Recombinant Proteins (administration & dosage, adverse effects, therapeutic use) Syndrome Thrombocytopenia (complications, drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!